Literature DB >> 11014621

Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients.

M Masiá Canuto1, F Gutiérrez Rodero, V Ortiz de la Tabla Ducasse, I Hernández Aguado, C Martín González, A Sánchez Sevillano, A Martín Hidalgo.   

Abstract

A point prevalence study to document oral yeast carriage was undertaken. Risk factors for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients were investigated with a case-control design. Cases included all patients with fluconazole-resistant strains (MIC> or =64 microg/ml), and controls were those with susceptible (MIC< or =8 microg/ml) or susceptible-dependent-upon-dose (MIC 16-32 microg/ml) strains. One hundred sixty-eight Candida strains were isolated from 153 (88%) patients, 28 (16%) of whom had oropharyngeal candidiasis. Overall, 19 (12%) of the patients harbored at least one resistant organism (MIC > or = 64 microg/ml). Among patients with resistant strains, tuberculosis (P<0.001), esophageal candidiasis (P = 0.001), clinical thrush (P<0.001), and a CD4 + cell count < 200/mm3 (P = 0.03) were more frequent. These patients had also been treated more commonly with antituberculous drugs (adjusted odds ratio [OR] 6.13; 95% confidence interval [CI] 2.11-17.80), ciprofloxacin (OR 6.0; 95% CI 1.23-29.26), fluconazole (OR 4.59; 95% CI 1.55-13.52), and steroids (OR 4.13; 95% CI 1.11-15.39). Multivariate analysis showed that the determinants for fluconazole resistance were therapy with antituberculous drugs (OR 3.61; 95% CI 1.08-12.07; P=0.03) and one of the following: previous tuberculosis (OR 3.53; 95% CI 1.08-14.57; P=0.03) or fluconazole exposure (OR 3.41; 95% CI 1.10-10.54). Findings from this study indicate that treatment with antituberculous drugs, previous tuberculosis, and fluconazole exposure are the strongest determinants for development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014621     DOI: 10.1007/s100960000323

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

Review 2.  Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.

Authors:  Andrew T Nishimoto; Cheshta Sharma; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

3.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Alia A Sarafandi; Tin Sein; Diana Mickiene; John Bacher; Andreas H Groll; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Authors:  Spencer W Redding; William R Kirkpatrick; Stephen Saville; Brent J Coco; William White; Annette Fothergill; Michael Rinaldi; Tony Eng; Thomas F Patterson; Jose Lopez-Ribot
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

6.  Epithelial GM-CSF induction by Candida glabrata.

Authors:  L Li; A Dongari-Bagtzoglou
Journal:  J Dent Res       Date:  2009-08       Impact factor: 6.116

7.  Pseudomembranous candidiasis in HIV/AIDS patients in Cali, Colombia.

Authors:  Luz Ángela Castro; María Inés Álvarez; Ernesto Martínez
Journal:  Mycopathologia       Date:  2012-10-21       Impact factor: 2.574

Review 8.  The oralome and its dysbiosis: New insights into oral microbiome-host interactions.

Authors:  Allan Radaic; Yvonne L Kapila
Journal:  Comput Struct Biotechnol J       Date:  2021-02-27       Impact factor: 7.271

9.  Host factors do not influence the colonization or infection by fluconazole resistant Candida species in hospitalized patients.

Authors:  Yun-Liang Yang; Ming-Fang Cheng; Ya-Wen Chang; Tzuu-Guang Young; Hsin Chi; Sai Cheong Lee; Bruno Man-Hon Cheung; Fan-Chen Tseng; Tun-Chieh Chen; Yu-Huai Ho; Zhi-Yuan Shi; Chung-Huang Hubert Chan; Ju-Yu Lin; Hsiu-Jung Lo
Journal:  J Negat Results Biomed       Date:  2008-12-16

Review 10.  Candida glabrata Biofilms: How Far Have We Come?

Authors:  Célia F Rodrigues; Maria Elisa Rodrigues; Sónia Silva; Mariana Henriques
Journal:  J Fungi (Basel)       Date:  2017-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.